Caisse DE Depot ET Placement DU Quebec Invests $12.58 Million in Esperion Therapeutics, Inc. (ESPR) Stock

Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $12,583,000. Caisse DE Depot ET Placement DU Quebec owned about 0.95% of Esperion Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ESPR. Vanguard Group Inc. raised its position in Esperion Therapeutics by 20.5% during the 1st quarter. Vanguard Group Inc. now owns 724,150 shares of the biopharmaceutical company’s stock worth $25,569,000 after buying an additional 123,318 shares during the last quarter. Geode Capital Management LLC raised its position in Esperion Therapeutics by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 136,521 shares of the biopharmaceutical company’s stock worth $4,820,000 after buying an additional 7,437 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Esperion Therapeutics by 174.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 110,475 shares of the biopharmaceutical company’s stock worth $3,901,000 after buying an additional 70,255 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Esperion Therapeutics by 20.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 55,129 shares of the biopharmaceutical company’s stock worth $1,947,000 after buying an additional 9,478 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Esperion Therapeutics by 73.3% in the 1st quarter. State Street Corp now owns 413,222 shares of the biopharmaceutical company’s stock valued at $14,592,000 after purchasing an additional 174,740 shares in the last quarter. Institutional investors own 92.27% of the company’s stock.

Esperion Therapeutics, Inc. (ESPR) opened at $53.14 on Thursday. Esperion Therapeutics, Inc. has a twelve month low of $10.71 and a twelve month high of $65.20.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the firm posted ($0.77) EPS. equities analysts expect that Esperion Therapeutics, Inc. will post -7.21 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on the stock. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Chardan Capital increased their price target on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday. Northland Securities reiterated a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a report on Friday, November 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Finally, Cowen assumed coverage on shares of Esperion Therapeutics in a report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price target for the company. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $60.15.

TRADEMARK VIOLATION WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/07/caisse-de-depot-et-placement-du-quebec-invests-12-58-million-in-esperion-therapeutics-inc-espr-stock.html.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

What are top analysts saying about Esperion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit